tiprankstipranks
Trending News
More News >
Krishna Institute of Medical Sciences Limited (IN:KIMS)
:KIMS
India Market
Advertisement

Krishna Institute of Medical Sciences Limited (KIMS) AI Stock Analysis

Compare
2 Followers

Top Page

IN:KIMS

Krishna Institute of Medical Sciences Limited

(KIMS)

Select Model
Select Model
Select Model
Neutral 62 (OpenAI - 4o)
Rating:62Neutral
Price Target:
₹747.00
▲(8.23% Upside)
Krishna Institute of Medical Sciences Limited demonstrates strong financial performance with robust revenue and profit growth, which is the most significant factor in its score. However, the technical analysis indicates a bearish trend, and the high P/E ratio suggests overvaluation, which negatively impacts the overall score.

Krishna Institute of Medical Sciences Limited (KIMS) vs. iShares MSCI India ETF (INDA)

Krishna Institute of Medical Sciences Limited Business Overview & Revenue Model

Company DescriptionKrishna Institute of Medical Sciences Limited (KIMS) is a leading healthcare provider in India, operating a chain of multi-specialty hospitals. The company offers a comprehensive range of healthcare services, including outpatient and inpatient care, advanced medical procedures, and diagnostic services. With a focus on delivering high-quality medical care, KIMS serves patients across various disciplines such as cardiology, orthopedics, neurology, oncology, and more.
How the Company Makes MoneyKIMS makes money primarily through its multi-specialty hospitals by offering a wide array of medical services. Revenue is generated from patient admissions, surgical procedures, consultations, and diagnostic services. The company also earns from specialized healthcare packages and preventive health check-ups. Additionally, KIMS benefits from collaborations with insurance providers, facilitating reimbursement for services rendered to insured patients. The company's strategic location of hospitals in urban and semi-urban areas allows it to cater to a large patient base, further driving its revenue growth.

Krishna Institute of Medical Sciences Limited Financial Statement Overview

Summary
Krishna Institute of Medical Sciences Limited shows strong financial health with robust revenue and profit growth, supported by stable margins. Despite increased leverage, the company maintains a solid equity base and strong operational cash generation, although high capital expenditures have led to negative free cash flow.
Income Statement
85
Very Positive
Krishna Institute of Medical Sciences Limited has demonstrated a robust revenue growth trajectory, increasing from 16.5 billion in 2022 to 30.4 billion in 2025, indicating strong market demand and operational efficiency. The gross profit margin remained stable around 62-63%, showcasing effective cost management. Notably, the net profit margin improved to 12.7% in 2025 from 12.4% in 2024, suggesting enhanced profitability. The EBIT margin also showed a strong increase to 62.9% in 2025, reflecting operational excellence. Overall, the company exhibits impressive growth and profitability.
Balance Sheet
78
Positive
The balance sheet of Krishna Institute of Medical Sciences Limited reflects a solid equity base with stockholders' equity increasing to 21.4 billion in 2025. The debt-to-equity ratio rose to 1.20 in 2025, indicating increased leverage which could pose a risk if not managed carefully. However, the equity ratio remains healthy at 37.3%, suggesting a stable financial foundation. Return on equity improved to 18% in 2025, signifying effective utilization of shareholder funds. While leverage has increased, the company maintains a strong equity position.
Cash Flow
72
Positive
The cash flow analysis reveals that operating cash flow has been steadily increasing, reaching 5.8 billion in 2025, highlighting robust operational performance. However, free cash flow has been negative, mainly due to high capital expenditures which could limit liquidity in the short term. The operating cash flow to net income ratio of 1.51 in 2025 suggests strong earnings quality. Despite the negative free cash flow, the company shows solid cash generation from operations.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue32.18B30.35B24.98B21.98B16.51B13.30B
Gross Profit22.12B9.10B14.82B6.99B10.34B4.19B
EBITDA8.24B7.83B6.53B6.51B5.42B3.78B
Net Income3.77B3.85B3.10B3.36B3.33B2.01B
Balance Sheet
Total Assets0.0057.36B38.52B29.41B19.07B14.36B
Cash, Cash Equivalents and Short-Term Investments1.02B1.02B1.32B1.34B1.90B2.84B
Total Debt0.0025.57B13.55B6.78B2.57B3.16B
Total Liabilities-24.19B33.17B17.59B10.03B4.97B5.60B
Stockholders Equity24.19B21.38B18.28B16.70B13.87B8.64B
Cash Flow
Free Cash Flow0.00-4.27B-1.26B-1.42B1.54B2.62B
Operating Cash Flow0.005.82B5.21B4.32B3.24B3.56B
Investing Cash Flow0.00-11.16B-7.53B-5.47B-4.12B-3.54B
Financing Cash Flow0.005.43B2.17B196.42M609.99M98.19M

Krishna Institute of Medical Sciences Limited Technical Analysis

Technical Analysis Sentiment
Negative
Last Price690.20
Price Trends
50DMA
736.33
Negative
100DMA
711.15
Negative
200DMA
659.40
Positive
Market Momentum
MACD
-11.56
Positive
RSI
37.36
Neutral
STOCH
39.25
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:KIMS, the sentiment is Negative. The current price of 690.2 is below the 20-day moving average (MA) of 726.23, below the 50-day MA of 736.33, and above the 200-day MA of 659.40, indicating a neutral trend. The MACD of -11.56 indicates Positive momentum. The RSI at 37.36 is Neutral, neither overbought nor oversold. The STOCH value of 39.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:KIMS.

Krishna Institute of Medical Sciences Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
77
Outperform
₹362.43B110.290.72%-53.19%-94.01%
75
Outperform
₹786.55B90.560.09%14.04%32.99%
71
Outperform
₹372.49B69.680.04%15.42%10.66%
68
Neutral
₹363.50B46.070.25%12.09%-2.79%
62
Neutral
₹282.42B75.0524.71%19.17%
61
Neutral
₹93.91B257.1616.85%-29.57%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:KIMS
Krishna Institute of Medical Sciences Limited
690.20
148.55
27.43%
IN:ASTERDM
Aster DM Healthcare Ltd.
696.75
282.53
68.21%
IN:FORTIS
Fortis Healthcare Ltd.
1,068.55
455.28
74.24%
IN:HCG
HealthCare Global Enterprises Ltd.
684.05
234.20
52.06%
IN:MEDANTA
Global Health Limited
1,373.65
335.42
32.31%
IN:NH
Narayana Hrudayalaya Ltd.
1,774.05
553.87
45.39%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 08, 2025